Steve Staben

Steve Staben, Ph.D. joined Lycia Therapeutics as Chief Scientific Officer in October 2021. Prior to Lycia, he spent over 14 years at Genentech leading drug discovery programs in oncology and immunology as well as new modality platforms. His basic research interests include new mechanisms for modulation of therapeutic targets, including applications of induced proximity. He has co-authored over 70 peer reviewed articles and patent applications. Steve holds his Ph.D. in organic chemistry from the University of California, Berkeley.